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Abstract 
Status epilepticus (SE) is related to significant mortality and morbidity. A reliable prognosis may 
help better managing medical resources and treatment strategies. We examined the role of 
preexisting comorbidities on the outcome of SE patients, an aspect that has received little attention 
to date. We prospectively studied incident SE episodes in 280 adults occurring over 55 months in 
our tertiary care hospital, excluding patients with post-anoxic encephalopathy. Different models 
predicting mortality and return to clinical baseline at hospital discharge were compared, which 
included demographics, SE etiology, a validated clinical SE severity score, and comorbidities 
(assessed with the Charlson Comorbidity Index) as independent variables. The overall short-term 
mortality was 14%, and only half of patients returned to their clinical baseline. On bivariate 
analyses, age, SE severity score, potentially fatal etiologies, and number of pre-existing 
comorbidities were all significant predictors of both mortality and return to clinical baseline. As 
compared to the simplest predictive model (including demographics and deadly etiology), adding 
SE severity and comorbidities resulted in an improved predictive performance (C-statistics 0.84 vs. 
0.77 for mortality, and 0.86 vs 0.82. for return to clinical baseline); comorbidities, however, were 
not independently related to outcome. Considering comorbidities and clinical presentation, in 
addition to age and etiology, slightly improves the prediction of SE outcome, regarding both 
survival and functional status. This analysis also emphasizes the robust predictive role of etiology 
and age.
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Status epilepticus (SE) represents a severe medical condition (Neligan & Shorvon, 2011); some 
independent predictors of dismal outcome have been identified, such as acute or potentially fatal 
etiology, advanced age, de novo presentation, and consciousness impairment before treatment 
(Towne et al., 1994; Logroscino et al., 1997; Rossetti et al., 2006). However, these variables 
encompass only a limited aspect of the clinical background. In fact, the role of previously existing 
medical problems has received far less attention. 
We undertook this analysis, in order to investigate how comorbidities influence SE outcome in 
addition to other known predictors.  
Methods 
Patients and procedures 
We analyzed a prospective registry including all adult patients (16 years and older) with SE 
admitted to our tertiary hospital between April 1st 2006 and October 31st 2010 (55 months). Details 
may be found elsewhere (Novy et al., 2010). Briefly, SE was defined as the continuous occurrence 
of seizures for more than 30 minutes (until 2008), and 5 minutes (since 2008), as suggested by the 
operational definition (Lowenstein et al., 1999). Seizures were diagnosed clinically, but EEG 
confirmation (at least 20 minutes recordings with background reactivity evaluation) was required 
for non-convulsive events. SE episodes were identified by the neurological consultants at our 
emergency and intensive care units, and by the EEG medical staff. Subjects with post-anoxic SE 
were not recorded. Only incident cases were considered, to allow to every SE episode an equal 
chance to reach all possible outcomes. This study was approved by our Ethic Commission. 
Variables 
Demographics, history of previous seizures, worst seizures type, level of consciousness before 
treatment, pharmacological treatments and SE etiology were recorded prospectively. The STESS 
score, a validated SE clinical severity score, including age, history of previous seizures, seizure type 
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and consciousness was calculated (0-6 points) (Rossetti et al., 2008a) (table 1 in supplementary 
material) and categorized in ≥ 3 (bad outcome prediction) versus < 3 (good outcome prediction). 
Etiology was considered “potentially fatal” if potentially leading to death if not specifically treated, 
as previously described (Rossetti et al., 2006). 
The Charlson Comorbidity Index (CCI), a validated score of 19 different medical conditions (table 
2 in supplementary material), was used to assess the comorbidities (Charlson et al., 1987). CCI was 
calculated after discharge, based on the medical files, by identification of all comorbid conditions 
present on admission (except SE etiology). The CCI was categorized in three groups: CCI=0, 
CCI=1-2, and CCI ≥3; we also analyzed every medical condition as an individual variable. The 
clinical condition at hospital discharge represented the primary outcome; it was prospectively 
collected and categorized into return to clinical baseline (premorbid functional and neurological 
status), new handicap, or death.  
Statistical analyses 
Potential predictors were analyzed for their relationship with the outcomes “return to baseline” and 
“mortality” using χ2 tests. Stepwise logistic regressions were performed to generate predictive 
models using potential predictors, including demographics, SE severity, etiology and comorbidities. 
Age was dichotomized at 65 years; of note, since the STESS includes age, the latter was omitted in 
models considering this score. Discrimination power was assessed using the C-statistics and 95% 
confidence intervals, and goodness of fit with the Hosmer-Lemeshow χ2 test; the AIC and BIC 
values were used as a rough comparison of the models among them, while formal comparisons 
among ROC were performed using a non-parametric approach. For multiple comparisons, we 
conservatively applied Bonferroni corrections to obtain a global P<0.05. Analyses were performed 
with version 9 of the Stata software (College Station, TX). 
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Results 
Among 335 SE events recorded during the study period, we indentified 280 incident episodes. 
Demographics and most relevant clinical variables of the cohort are illustrated in Table 1. Twenty 
(7%) episodes lasted between 5-29 minutes. Gender was evenly distributed, the mean age was 59.3 
(± 18.5) years, and 59% of patients had a de novo SE episode. Slightly more than half of the 
subjects displayed a severely impaired consciousness (only 2.5% had a nonconvulsive status 
epilepticus in coma), or potentially fatal SE etiologies. Among the most frequent causes, 13.9% of 
SE were symptomatic of primary brain tumor or meningioma, 12.9% had a central nervous system 
hemorrhage, 9.7% were symptomatic of an old stroke; 9.6% had a cryptogenic SE. In 55.4% of 
patients a severe SE was retained (STESS ≥ 3); 10.7% of patients received coma induction for SE 
treatment. About one third of patients did not have any prior comorbidity, while one third had a 
moderate, and the last third presented a high comorbidity index.  
The overall short-term mortality was 14%, and only half of patients returned to baseline conditions 
at hospital discharge. In bivariate analyses, age, STESS scores, potentially fatal etiologies, and an 
increased number of comorbidities were significant predictors of both outcomes, while gender was 
not (for more details, see table 3 in supplementary material). 
Considering in-hospital mortality, all models’ calibrations were acceptable and are illustrated in 
Figure 1A; the comparison of the 6 models did not show any significant difference (p=0.1325, χ2) 
(for more details about model’s calibration, see table 4A in supplementary material). Pairwise 
analyses were performed using p<0.017 (0.05/3) as a significant threshold. Compared to the 
simplest model (Model 0), the model including the STESS (Model 1, p=0.166, χ2) and the best 
model including CCI (Model 3, p=0.064, χ2) were not statistically different.  The model including 
both STESS and CCI was better (Model 5, p=0.0158, χ2), showing a slight improvement of the 
ROC area (0.77 versus 0.84).  
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We used a similar approach for return to baseline clinical condition (Figure 1B). All models’ 
calibrations were acceptable, except for Model 15 (for more details about model’s calibration, see 
table 4B in supplementary material). The comparison of the 6 models indicated some heterogeneity 
(p=0.0403, χ2). The best model, including CCI (model 13), was better than the simplest model 
(Model 00, p=0.0043, χ2), corresponding to a modest improvement of the ROC area (0.82 versus 
0.86). 
To summarize, the best predictive models included: etiology, STESS and each variable of the CCI 
for mortality (Model 5), and demographics, etiology and each variable of the CCI for return to 
clinical baseline conditions (Model 13). 
 
Discussion 
This study shows that medical comorbidities increase relatively marginally the prediction accuracy 
of SE outcome, and confirms that age and etiology are robust outcome prognosticators in this 
setting.  
Our results are in line with those of previous studies performed on different cohorts (Towne et al., 
1994; Logroscino et al., 1997; Rossetti et al., 2006) that identified age and SE etiology as the main 
independent outcome predictors. In addition, one recent work suggested that patients with a higher 
number of comorbid conditions have a worse outcome (Koubeissi & Alshekhlee, 2007). However, 
this large data-based study, focused on convulsive SE, has important limitations: its design included 
a retrospective identification of subjects with SE and their comorbidities assessment was based on 
ICD diagnoses (Rossetti et al., 2008b). Moreover the short-term mortality of 3% seems unusually 
low in this clinical setting, and concomitant medical diagnoses were only identified as independent 
prognostic factors, without any specific analysis addressing their added value in prognostic models 
including other major predictors.  
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Regarding etiology, as SE is often one of the clinical manifestations of brain injury, it seems logical 
that the nature of that injury will markedly influence prognosis. A massive and irreversible damage 
predicts per se a devastating outcome, whereas reversible conditions such as anticonvulsant drug 
withdrawal may herald a more favorable outcome after SE. As previously outlined (Rossetti et al., 
2006; Novy et al., 2010), “acute etiologies” are less robust in predicting outcome than “potentially 
fatal” etiologies; this may be related to the fact that the latter encompass those acute and 
progressive symptomatic etiologies that are more dangerous for the patient.  
Our study is limited to a hospital-based cohort, but since SE represents a condition that is 
predominantly treated at hospitals, this aspect should not affect our results. The second limitation 
lies in the fact that we only investigated the effect of comorbidities on prognosis at hospital 
discharge, but we cannot exclude that long-term prognosis may be influenced by comorbidities. The 
strength of our study builds on its prospective design, and the use of clearly defined inclusion 
criteria. Our mortality rate (14%), which is in the middle range of population-based assessments in 
Europe and the US over the last two decades: 7% (Coeytaux et al., 2000) and 22% (DeLorenzo et 
al., 1996), corroborates our findings. Finally, any score may not reflect exactly the clinical 
background of a patient, but because the CCI is widely used and validated, it seems to be a 
reasonable choice to represent patient’s comorbidities. 
In conclusion, comorbidities and the clinical presentation seem to affect the outcome of SE in a 
relatively marginal way, while age and etiology appear as robust and widely applicable predictors. 
This emphasizes the importance of a thorough search for the underlying cause of SE in the clinical 
setting. Moreover, because the presence of comorbidities does not necessarily predict a bad 
outcome, this should not dissuade physicians from treating patients with SE and comorbid 
conditions appropriately. Obviously, comorbidities are important regarding contraindications and 
side effects of anti-epileptic drugs. In this regard they may influence the outcome by influencing the 
utilization of specific treatments. 
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Tables & Figures: 
Table 1: Tertiary care hospital SE patients’ demographics and clinical characteristics 
 
Demographic Data Number (proportion) 
  
Gender (Male) 139 (49.6%) 
Age (SD) 59.3 (18.5) 
Presence of previous seizures 115 (41%) 
Severe conscious impairment (stuporous 
or comatous) before treatment 159 (56%) 
Deadly etiology 129 (46%) 
STESS ≥3 155 (55.4%) 
Coma induction for SE treatment 30 (10.7%) 
Charlson Comorbidity Score  
1 75 (26.8%) 
2 or 3 100 (35.7%) 
≥3 105 (35.5%) 
Comorbidities (according to Charlson et al., 1987)  
Cerebrovascular disease 61 (21.8%) 
Any tumor 58 (20.7%) 
Chronic pulmonary disease 31 (11%) 
Solid metastatic tumor 31 (11%) 
Congestive heart disease 25 (8.9%) 
Moderate/severe renal disease 23 (8.2%) 
Dementia 22 (7.9%) 
Myocardial infarction 21 (7.5%) 
Peptic ulcer 21 (7.5%) 
Peripheral vascular disease 18 (6.4%) 
Hemiplegia 16 (5.7%) 
Moderate /severe liver disease 14 (5%) 
Mild liver disease 11 (3.9%) 
Diabetes 9 (3.2%) 
HIV 6 (2.1%) 
Connective tissue disease 4 (1.4%) 
Lymphoma 4 (1.4%) 
Diabetes with organ damage 2 (0.7%) 
Leukemia 2 (0.7%) 
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Figure 1: Comparison of 6 predictive models (with model’s construction) 
A: for the outcome “mortality”: 
• Model 0 : Gender, age, potentially fatal etiology 
• Model 1 : Gender, potentially fatal etiology, STESS 
• Model 2 : Gender, age, potentially fatal etiology, categorized CCI 
• Model 3 : Gender, age, potentially fatal etiology, each variable of CCI 
• Model 4 : Gender, potentially fatal etiology, STESS, categorized CCI 
• Model 5 : Gender, potentially fatal etiology, STESS, each variable of CCI 
 
B: for the outcome “Return to base line”: 
• Model 00 : Gender, age, potentially fatal etiology 
• Model 11 : Gender, potentially fatal etiology, STESS 
• Model 12 : Gender, age, potentially fatal etiology, categorized CCI 
• Model 13 : Gender, age, potentially fatal etiology, each variable of CCI 
• Model 14 : Gender, potentially fatal etiology, STESS, categorized CCI 
• Model 15 : Gender, potentially fatal etiology, STESS, each variable of CCI 
 

